Acetylon Pharmaceuticals Initiates New Phase 1b Clinical Trial of Rocilinostat (ACY-1215) in Combination with Celgene’s Revlimid® (Lenalidomide) and Dexamethasone for Patients with Multiple Myeloma
09:00 EDT 1 Aug 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Acetylon Pharmaceuticals today announced it has initiated patient
enrollment in a new Phase 1b clinical trial of its lead drug candidate
rocilinostat (ACY-1215) in combination with Revlimid® (lenalidomide) and
dexamethasone for...
Other Sources for this Article
Acetylon Pharmaceuticals, Inc.
Walter C. Ogier, 617-245-1300
President
and Chief Executive Officer
wogier@acetylon.com
or
MEDIA:
MacDougall
Biomedical Communications
Kari Watson, 781-235-3060
kwatson@macbiocom.com
More From BioPortfolio on "Acetylon Pharmaceuticals Initiates New Phase 1b Clinical Trial of Rocilinostat (ACY-1215) in Combination with Celgene’s Revlimid® (Lenalidomide) and Dexamethasone for Patients with Multiple Myeloma"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
